It’s worth noting that NB tumors are predominantly characterized by low or negative expression of major histocompatibility complex (MHC), making it challenging for tumor-reactive CD8+ T cells to recognize and target these tumors, as they typically identify tumor antigens presented through the MHC I antigen presentation pathway [55]. The gene discussed is CD8A; the disease is neoplasm.